Checkpoint Combo Tops Single Agent in Advanced Ovarian Cancer

]]>(MedPage Today) -- Dual immune-checkpoint inhibition almost tripled the response rate in patients with advanced ovarian cancer as compared with a single agent, a small randomized trial showed.The overall response rate increased from 12.2% with...